Bromazepam tablets

Each tablet contains:
Bromazepam..................1.5 mg, 3mg or 6 mg

Chemically, bromazepam is 7-bromo-1,3-dihydro-5-(2-pyridinyl)-2H-1,4-benzodiazepine-2-on

Drug description:
1.5mg yellow tablets; 3mg pink tablets. Both hexagonal scored tablets marked L and tablet strength.

Presentation:
Tablets, bromazepam 1.5 mg, 3mg. Lexotan is not prescribable on the NHS.

Indications:
Short-term treatment of anxiety that is severe or disabling occurring alone or with insomnia.

Adult Dosage:
3 - 18 mg daily in divided doses.

Child Dosage:
Not recommended.

Elderly Dosage:
1.5 - 9 mg daily in divided doses.

Contra Indications:
Acute pulmonary insufficiency, respiratory depression, phobic or obsessional states, chronic psychosis, myasthenia gravis. Pregnancy, labour and lactation.

Special Precautions:
Chronic pulmonary insufficiency, chronic renal or hepatic disease. The elderly. Judgement and dexterity may be impaired, patients should be warned of these effects.

Do not use alone to treat depression or anxiety associated with depression. In cases of bereavement, psychological adjustment may be impaired. Avoid long-term use; withdraw gradually.

Interactions:
Alcohol and other CNS depressants, anticonvulsants, narcotic analgesics, cimetidine, rifampicin.

Adverse Reactions:
Drowsiness, light-headedness, muscle weakness, ataxia, confusion, vertigo, GI upset, skin rashes, impaired alertness and dexterity. Urinary retention, changes in libido.

Rarely blood disorders and jaundice. Abnormal psychological reactions. Risk of dependence increases the higher the dose and the longer the treatment.

For Information about Generic Medicines: genericmedicines@tajpharma.com

Note: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).
DISCLAIMER

THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION.

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “expected”, “plan”, “goal”, “believe”, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company’s control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as “relevant persons”). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.
About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufacturers pharmaceutical formulations and API for India and other countries of the world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.